Filing Flows › Zevra Therapeutics (ZVRA) › Capital expenditures
Zevra Therapeutics (ZVRA) capital expenditures by quarter
Zevra Therapeutics' capital expenditures were $238K in Q3 2026 (third quarter 2026), +10% from Q2 2026. Over the last 4 quarters it ranged from $35K (Q1 2026) to $554K (Q3 2025).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $238K | +10% | -57% |
| Q2 2026 | $217K | +520% | — |
| Q1 2026 | $35K | -94% | — |
| Q3 2025 | $554K | — | — |
Q3 2026 at a glance
Zevra Therapeutics, Q3 2026: revenue $37.8M (+45% year over year), operating margin 30.7%, net earnings $19.2M, operating cash flow $10.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Zevra Therapeutics' capital expenditures?
Zevra Therapeutics' capital expenditures were $238K in Q3 2026 (third quarter 2026), +10% from Q2 2026.
How has Zevra Therapeutics' capital expenditures changed?
Over the last 4 quarters it ranged from $35K (Q1 2026) to $554K (Q3 2025).